Does Neoadjuvant Androgen Deprivation Therapy Before Primary Whole Gland Cryoablation of the Prostate Affect the Outcome?

The oncologic results of cryoablation in prostate cancer patients with bone metastases

“…More investigations should focus on prognosis factors, including informative genomic profiling of primary specimens [22], the oncological response to systemic treatment (such as ADT or chemotherapy) [23], the synthetic modality (neoadjunctive ADT or adjunctive ADT) [24], and even the immune response after treatment (such as the cryoimmunologic response) [25]. These studies could identify prognostic markers and ultimately guide-targeted treatment.…”

Salvage focal prostate cryoablation for locally recurrent prostate cancer after radiotherapy: Initial results from the cryo on-line data registry

“…Multiple studies demonstrate that neoadjuvant hormone ablation can improve bDFS in patients who undergo radiotherapy, but not in patients who undergo radical prostatectomy . Grossgold et al reported that neoadjuvant hormone ablation did not have an impact on bDFS in patients who undergo primary prostate cryoablation. In the present study, patients who underwent salvage focal cryoablation combined with neoadjuvant hormone ablation were compared to patients who underwent salvage focal cryoablation alone.…”

The Effect of Androgen Deprivation Therapy Before Salvage Whole-gland Cryoablation After Primary Radiation Failure in Prostate Cancer Treatment

“…Additionally, our results corroborate the lack of benefit for neoadjuvant ADT in combination with cryotherapy. 16 Overall, the low urinary fistula rates occurring in both pre-SC ADT and no ADT groups testified to the improved safety of the newer generations of cryotherapy technology. The lower incidence of urinary retention and incontinence in patients receiving pre-SC ADT may be related to the cytoreductive effect provided by neoadjuvant ADT.…”

“…23,24 The present study aims to clarify whether the use of neoadjuvant ADT before salvage Cryoablation can prolong cancer-free survival. We hypothesized that as neoadjuvant ADT showed no benefit before primary whole-gland cryotherapy, 16 the use of ADT after biochemical recurrence will also have little oncologic benefit. On the contrary, the administration of ADT may delay definitive salvage therapy, thus missing the therapeutic window for many patients who initially present with localized recurrent disease and subsequently progress.…”

“…[12][13][14][15] In contrast, a recent study demonstrated that neoadjuvant ADT did not affect biochemical recurrence after primary cryoablation of the prostate. 16 The role of ADT in the salvage setting remains unclear. In this study, we use information obtained from the Cryo On-Line Database (COLD) in an attempt to define the effects of ADT before salvage prostate cryoablation.…”